WASHINGTON - The Trump administration has bought up virtually all stocks for the next three months of a drug shown to work against Covid-19.
The US Department of Health and Human Services (HSS) said it had secured more than 500,000 treatment courses of remdesivir for American hospitals.
This represents 100% of the US pharmaceutical firm Gilead's projected production for July (94,200 treatment courses), 90% of production in August (174,900 treatment courses), and 90% of production in September (232,800 treatment courses), alongside an allocation for clinical trials.
Remdesivir is an anti-viral drug that was developed for use against Ebola.
It has been approved for use in Covid-19 patients by the US and the UK, among other countries, after data suggested it can cut recovery time by about four days.
However, there is no clinical trial data as yet to suggest it improves survival from coronavirus.
HHS secretary Alex Azar said in a statement: "President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19.
"To the extent possible, we want to ensure that any American patient who needs remdesivir can get it.
"The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people."
It does raise two very important questions: what is a fair price for a drug, and what is fair access to a drug
Oxford University's Professor Peter Horby, chairman of the New and Emerging Respiratory Virus Threats Advisory Group (Nervtag), said manufacturer Gilead would be under "certain political pressures locally" as a US company.
He told BBC Radio 4's Today programme: "It does raise two very important questions: what is a fair price for a drug, and what is fair access to a drug, and those are common issues but are particularly important in a global crisis like this.(FA)